Mergers & Acquisitions Mergers & Acquisitions

AstraZeneca, Alexion need antitrust approval from 13 jurisdictions, including US, EU, UK, Brazil, South Korea, Japan

By Flavia Fortes
  • 10 Mar 2021 10:54
  • 15 Mar 2021 06:13
AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals needs clearance from antitrust authorities from 13 jurisdictions, including the United States, the European Union, the UK, Brasil, South Korea and Japan.
Canada, Colombia, Israel, Morocco, Russia, Taiwan and Turkey are also on the list, which was disclosed by the companies in their filing

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers


Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

Latest News